GSK plc Fair Value: 35.8% Upside at £19.62

GSK plc Fair Value Analysis: 35.8% Upside Potential

GSK plc (LSE: GSK) currently trades at £19.62, well below our calculated fair value of £26.64. This implies a compelling 35.8% upside, with a Quality Score of 74/100. Our multi-model approach across 21 valuation frameworks flags the stock as undervalued.

What GSK plc Does

GSK plc is a global biopharmaceutical leader focused on vaccines, specialty medicines and general medicines. Its portfolio spans respiratory diseases, oncology, HIV, infectious diseases and consumer healthcare. Key growth drivers include the Shingrix shingles vaccine and a broadening specialty pipeline in areas such as respiratory and oncology.

Recent Performance and Market Context

In Q1 2026 GSK delivered solid results, with group sales rising 5% to £7.6 billion. Specialty Medicines grew 14%, boosted by new launches and strong demand, while Shingrix achieved record sales. Core operating profit increased 10% and core EPS rose 9%. Management reaffirmed full-year guidance of 3-5% sales growth and 7-9% growth in core operating profit and EPS. Q2 2026 results are due on 28 July.

Why Our Fair Value Model Sees Undervaluation

Despite robust earnings momentum and a high-quality business, GSK plc trades at a meaningful discount to our intrinsic value estimate. The gap reflects market caution around near-term patent dynamics and macro pressures, yet our models incorporate the company’s improving product mix, strong cash generation and attractive dividend yield. The 74/100 Quality Score underscores a solid balance sheet, competitive moat in vaccines and disciplined capital allocation.

Key valuation drivers include:

• High-margin Specialty Medicines expansion
• Recurring revenue from flagship vaccines
• Pipeline optionality in late-stage assets
• Consistent free-cash-flow conversion

Check GSK plc yourself using the free Fair Value Calculator to run your own scenarios across our 21 models.

Main Risks to Consider

Investors should weigh several factors. Patent expirations on older products could pressure certain franchises. Regulatory approvals, clinical trial outcomes and competition in oncology and respiratory markets remain uncertainties. Currency movements and healthcare policy changes also feature. The upcoming Q2 results will provide further clarity on momentum.

Balanced Verdict

GSK plc presents an attractive risk-reward profile at current levels. Our fair value of £26.64 suggests meaningful upside, supported by operational strength and a credible growth trajectory. While not without risks, the discount to intrinsic value offers a margin of safety for long-term investors. For the latest data and to explore other stocks, visit our fair value calculator.

Frequently Asked Questions

Is GSK plc undervalued right now?

Our analysis shows GSK plc trading at a 35.8% discount to its fair value of £26.64, supporting an undervalued verdict based on 21 valuation models.

What drove GSK's Q1 2026 results?

Strong 5% sales growth to £7.6bn was led by 14% growth in Specialty Medicines and record Shingrix vaccine sales, with core operating profit rising 10%.

What are the main risks for GSK shareholders?

Key risks include patent expirations, regulatory hurdles, pipeline setbacks, competition in vaccines and oncology, and upcoming Q2 results on 28 July 2026.

Sources

Context gathered via live web search while writing this article:

• https://finance.yahoo.com/quote/GSK/earnings/GSK-Q1-2026-earnings_call-551544.html/
• https://india-pharma.gsk.com/en-in/investors/quarterly-results/
• https://www.hl.co.uk/shares/share-research/gsk-q1-results-strong-start-no-upgrade
• https://www.youtube.com/playlist?list=PLvDyxtKlIcnisf7_oSH7dTWkvqyThzUn5
• https://tickeron.com/ticker/GSK/
• https://finance.yahoo.com/news/too-consider-gsk-lse-gsk-081927957.html
• https://www.gsk.com/en-gb/investors/quarterly-results/
• https://www.gsk.com/media/5qjlbu5u/q1-2026-results-slides.pdf

Educational analysis only — not financial advice and not a buy or sell recommendation. Valuations are model-based and may be wrong; past performance does not indicate future results.